Hypertrophic and Keloid Scar Treatment Market Report 2026

The hypertrophic and keloid scar treatment market size has grown strongly in recent years. It will grow from $8.49 billion in 2025 to $9.33 billion in 2026 at a compound annual growth rate (CAGR) of 9.9%. The growth in the historic period can be attributed to increasing number of surgical procedures, rising incidence of trauma and burns, widespread use of corticosteroid injections, growth of dermatology and cosmetic clinics, clearly visible aesthetic impact of scars.

The hypertrophic and keloid scar treatment market size is expected to see rapid growth in the next few years. It will grow to $13.77 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to growing preference for non-invasive scar treatments, increasing adoption of laser and radiotherapy techniques, rising awareness of early scar management, expansion of combination treatment protocols, improving access to advanced dermatology services. Major trends in the forecast period include increasing adoption of combination scar management therapies, rising demand for minimally invasive and non-surgical treatments, growing use of laser and energy-based scar revision techniques, expansion of post-surgical and preventive scar care solutions, higher focus on early intervention and long-term scar control.

An increase in the number of road accidents and burn cases is expected to drive the growth of the hypertrophic and keloid scar treatment market going forward. Road accidents are incidents occurring on the road involving at least one vehicle and individuals. Such accidents and burn injuries require timely attention and appropriate treatment measures. Hypertrophic and keloid scar treatments are used to manage scars resulting from these injuries by reducing their height and tightness. The rise in road accidents and burn cases contributes to market growth. For example, in January 2025, The Health Foundation, a UK-based independent organization, reported that in 2023, there were 43 serious or fatal casualties per billion miles traveled by car, compared with 1,032 for cyclists and 1,914 for motorcyclists, while 92 pedestrians per million residents were killed or seriously injured. Therefore, the increase in road accidents and burn cases is expected to drive the hypertrophic and keloid scar treatment market.

Growing aesthetic procedures are also anticipated to propel the hypertrophic and keloid scar treatment market forward. Aesthetic procedures refer to non-invasive or minimally invasive cosmetic treatments aimed at enhancing a person’s appearance and addressing cosmetic concerns. Hypertrophic and keloid scar treatments are applied in these procedures to improve the appearance of raised scars, contributing to a smoother and more aesthetically pleasing outcome. For instance, in June 2024, The International Society of Aesthetic Plastic Surgery (ISAPS), a US-based organization for plastic surgeons, reported that in 2023, liposuction remained the leading surgical procedure with over 2.2 million procedures performed, maintaining its 2022 ranking. Following closely were breast augmentation and eyelid surgery, which saw significant growth. Eyelid surgery increased by 24%, reaching over 1.7 million procedures, while rhinoplasty rose by 21.6%, totaling 1.1 million procedures compared to the previous year. Consequently, the growth of aesthetic procedures is supporting the expansion of the hypertrophic and keloid scar treatment market.

Key companies in the hypertrophic and keloid scar treatment market are focusing on developing clinically proven solutions using silicon, such as medical-grade silicone strips, to maximize profitability. Medical-grade silicone strips are therapeutic products made from high-quality silicone, specifically designed to promote scar healing and reduction. For example, in April 2023, Scar Erase, a UK-based company specializing in silicone-based scar reduction therapies, launched Scar Erase silicone strips, a clinically tested and affordable solution for scar management. Made from 3mm medical-grade silicone, these strips are effective for various scar types, including hypertrophic, keloid, post-surgery, and stretch marks. The silicone technology encapsulates the scar, promoting hydration and an optimal healing environment, leading to noticeable improvements in scar texture, color, and height. The strips are designed for comfort and discretion, providing an accessible at-home treatment option.

Major companies operating in the hypertrophic and keloid scar treatment market are Smith & Nephew plc, Merz Pharmaceutical LLC, Lumenis Ltd., Enaltus LLC, Sonoma Pharmaceuticals Inc., Molnlycke Health Care AB, Suneva Medical Inc., Pacific World Corporation, Perrigo Company plc, Cynosure Inc., Alliance Pharma plc, Newmedical Technology Inc., HRA Pharma, Scar Heal Inc., McKesson Medical Surgical Inc., Johnson & Johnson Private Limited, Medtronic plc, 3M Company, Sinclair Pharma plc, Avita Medical, Stratpharma AG, Biodermis, Mederma, Silagen.

North America was the largest region in the hypertrophic and keloid scar treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global hypertrophic and keloid scar treatment market report during the forecast period. The regions covered in the hypertrophic and keloid scar treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hypertrophic and keloid scar treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the hypertrophic and keloid scar treatment market by raising costs for imported laser devices, radiotherapy equipment, and specialty injectable drugs, affecting treatment affordability and clinic investment decisions. These effects are more pronounced in regions dependent on imported aesthetic and dermatology technologies, particularly in emerging markets. At the same time, tariffs are encouraging localized manufacturing of topical products and injectables, as well as innovation in cost-effective scar management solutions, supporting long-term market growth.

The hypertrophic and keloid scar treatment market research report is one of a series of new reports that provides hypertrophic and keloid scar treatment market statistics, including hypertrophic and keloid scar treatment industry global market size, regional shares, competitors with a hypertrophic and keloid scar treatment market share, detailed hypertrophic and keloid scar treatment market segments, market trends and opportunities, and any further data you may need to thrive in the hypertrophic and keloid scar treatment industry. This hypertrophic and keloid scar treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hypertrophic and keloid scar treatment refers to therapies for scars that remain within the boundaries of the original wound or extend beyond it into surrounding skin. Hypertrophic scars are confined to the area of injury, whereas keloids grow outside the original wound boundaries and typically do not regress over time.

The primary treatments in the hypertrophic and keloid scar treatment market include cryotherapy, surgical excision, pressure dressings, intralesional 5-fluorouracil, superficial X-ray therapy, intralesional corticosteroid injections, and other approaches. Cryotherapy is a medical procedure that uses an extremely cold liquid or a cryoprobe to freeze and eliminate abnormal tissue, targeting the core of the keloid scar while preserving surface-level cells and tissue. Treatment products include topical formulations, laser devices, injectables, and other therapies designed for hypertrophic and keloid scars. Key end-users of these treatments include hospitals, clinics, and other healthcare facilities.

The hypertrophic and keloid scar treatment market consist of revenues earned by entities by providing occlusive dressings, compression therapy, intralesional corticosteroid injections, cryosurgery, excision, radiation therapy, laser therapy, interferon (IFN) therapy, doxorubicin, bleomycin, and verapamil. The market value includes the value of related goods sold by the service provider or included within the service offering. The hypertrophic and keloid scar treatment market also includes sales of skin camouflage, silicon gels, and skin needling. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.